SEPT2 and SEPT11 are upregulated in renal cell carcinoma (RCC), an aggressive and highly metastatic cancer of the kidney with poor response to therapeutics (Craven et al., 2006; Craven, Stanley, et al., 2006). Here, SEPTIN2 is linked to renal cell carcinoma.